State of the art in coronary revascularization: Everolimus eluting stents versus multiple arterial grafting

被引:6
|
作者
Benedetto, Umberto [1 ]
Caputo, Massimo [1 ]
Vohra, Hunaid [1 ]
Bryan, Alan [1 ]
Angelini, Gianni D. [1 ]
机构
[1] Univ Bristol, Bristol Heart Inst, Sch Clin Sci, Bristol, Avon, England
关键词
Coronary artery bypass grafting; Multiple arterial grafts; Everolimus-eluting stent; Multivessel coronary artery disease; BYPASS-SURGERY; NETWORK METAANALYSIS; MULTIVESSEL DISEASE; SURVIVAL; MORTALITY; DEATH; CABG;
D O I
10.1016/j.ijcard.2016.06.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Contemporary comparisons on coronary revascularization should take into account the state of the art percutaneous coronary intervention (PCI) with new generation everolimus-eluting stents (EESs) and coronary artery bypass grafting (CABG) with multiple arterial grafts (MAGs). We aimed to compare early outcomes and late survival after EES versus MAG in patients with multivessel coronary artery disease using a single centre institutional database. Methods: In an observational registry study, we identified 3787 patients with multivessel coronary disease. Of these 696 (18.3%) underwent PCI with EES and 3091 (81.7%) CABG with MAG. With the use of propensity-score matching, we identified 483 pairs for final comparison (C-statistic: 0.91). Results: The two groups were comparable for 30-day mortality (1.6% versus 0.8% in the EES and MAG group respectively, P = 0.38). Stroke was not observed in the EES group and it was 0.8% in the MAG group (P = 0.13). After a mean follow-up of 3.1 years, PCI with EES was associated with a higher risk of late death (HR 2.2; 95% CI 1.18-4.16; P = 0.01). Conclusions: In patients with multivessel coronary disease, CABG with multiple arterial grafts when compared with PCI with new generation drug eluting stent, was associated with significantly improved long-term survival. Further randomized studies are warranted to identify the best revascularization strategies in the current era. Crown Copyright (C) 2016 Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:345 / 349
页数:5
相关论文
共 50 条
  • [21] Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice)
    Smits, Pieter C.
    Vlachojannis, Georgios J.
    McFadden, Eugene Patrick
    Royaards, Kees-Jan
    Wassing, Jochem
    Joesoef, Kaiyum Sheik
    van Mieghem, Carlos
    van de Ent, Martin
    JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (09) : 1157 - 1165
  • [22] Everolimus-eluting stents reduce target revascularization compared with zotarolimus-eluting stents in patients with coronary artery disease: a meta-analysis
    Sakurai, Ryota
    CIRCULATION, 2012, 125 (19) : E866 - E867
  • [23] Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials
    Planer, David
    Smits, Pieter C.
    Kereiakes, Dean J.
    Kedhi, Elvin
    Fahy, Martin
    Xu, Ke
    Serruys, Patrick W.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (10) : 1104 - 1115
  • [24] Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice
    Zanchin, Christian
    Ueki, Yasushi
    Zanchin, Thomas
    Haner, Jonas
    Otsuka, Tatsuhiko
    Stortecky, Stefan
    Koskinas, Konstantinos C.
    Siontis, George C. M.
    Praz, Fabien
    Moschovitis, Aris
    Hunziker, Lukas
    Valgimigli, Marco
    Pilgrim, Thomas
    Heg, Dik
    Windecker, Stephan
    Raber, Lorenz
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (17) : 1665 - 1675
  • [25] Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents RESPONSE
    Zhang, Xin-Lin
    Xu, Biao
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (11) : 829 - 829
  • [26] Meta-analysis comparing sirolimus bioresorbable scaffolds versus everolimus-eluting metallic stents in coronary arterial disease
    Prasad, R. P.
    Al-Abcha, A. A.
    Elshafie, A.
    Radwan, Y. A.
    El-Sayed, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1230 - 1230
  • [27] Everolimus Eluting Stents Are Safer and Efficacious Than Paclitaxel Eluting Stents in Coronary Artery Disease
    Kodumuri, Vamsi K.
    Adigopula, Sashikanth
    Singh, Param P.
    Bedi, Updesh S.
    Molnar, Janos
    Arora, Rohit
    Khosla, Sandeep
    CIRCULATION, 2010, 122 (21)
  • [28] Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus
    Waksman, Ron
    Shlofmitz, Evan
    Windecker, Stephan
    Koolen, Jacques J.
    Saito, Shigeru
    Kandzari, David
    Kolm, Paul
    Lipinski, Michael J.
    Torguson, Rebecca
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (07): : 1020 - 1026
  • [29] Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease
    Dangas, George D.
    Serruys, Patrick W.
    Kereiakes, Dean J.
    Hermiller, James
    Rizvi, Ali
    Newman, William
    Sudhir, Krishnankutty
    Smith, Robert S., Jr.
    Cao, Sherry
    Theodoropoulos, Kleanthis
    Cutlip, Donald E.
    Lansky, Alexandra J.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (09) : 914 - 922
  • [30] 4-Year outcome of bioactive stents versus everolimus-eluting stents in acute coronary syndrome
    Karjalainen, Pasi P.
    Niemela, Matti
    Pietila, Mikko
    Sia, Jussi
    de Belder, Adam
    Rivero-Crespo, Fernando
    de Bruyne, Bernard
    Nammas, Wail
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2016, 50 (04) : 218 - 223